Tarsus Pharmaceuticals (TARS) vs Xenon Pharmaceuticals (XENE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tarsus Pharmaceuticals (TARS) has outperformed Xenon Pharmaceuticals (XENE) over the past year, gaining 7.6% versus a loss of 7.0%. Over five years, TARS leads with a +158.1% price change compared with +8.2% for XENE. Xenon Pharmaceuticals is the larger company by market cap ($3.53 billion vs $3.44 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TARS | XENE |
|---|---|---|
| Share price | $73.61 | $36.41 |
| Market cap | $3.44B | $3.53B |
| 1-day change | -0.67% | -0.44% |
| YTD return | -10.10% | -18.76% |
| 1-year return | +7.59% | -7.02% |
| 5-year return | +158.10% | +8.17% |
| EPS (TTM) | $-1.07 | $-4.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $91.53 | $72.66 |
| 52-week low | $53.89 | $35.75 |
| Distance from 52-week high | -19.58% | -49.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +35.17% | +101.51% |
| Average volume | 906.66K | 1.47M |
| Shares outstanding | 46.79M | 96.84M |
| Employees | 370 | 358 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TARS has outperformed XENE by 14.6 percentage points over the past year.
About Tarsus Pharmaceuticals
TARS stock →Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 370 employees
About Xenon Pharmaceuticals
XENE stock →Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 358 employees
TARS vs XENE FAQ
Which is bigger, Tarsus Pharmaceuticals or Xenon Pharmaceuticals?
Xenon Pharmaceuticals (XENE) is larger, with a market capitalization of $3.53B compared with $3.44B for Tarsus Pharmaceuticals (TARS).
Which stock has performed better over the past year, TARS or XENE?
TARS returned +7.59% over the past 12 months, compared with -7.02% for XENE (price return, excluding dividends). Past performance does not predict future results.
Are Tarsus Pharmaceuticals and Xenon Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Tarsus Pharmaceuticals and Biotechnology: Pharmaceutical Preparations for Xenon Pharmaceuticals.